On July 3, True Health Medical-B declined 7.89% in regular trading, trading at 416.0 HKD/share, with turnover of HK$9.3575 million.

The decline comes as a technical correction following an extraordinary post-IPO surge. The company listed on the Hong Kong Stock Exchange on June 30 at an offer price of HK$126.20 per share, backed by 1,790.4 times oversubscription in the Hong Kong public offering. On its debut day, the stock closed at HK$400, representing a gain of approximately 217%. The stock continued to climb on July 2, rising over 21% intraday. The rapid accumulation of short-term gains has now triggered profit-taking pressure.

The company is engaged in the research, development, and commercialization of percutaneous puncture surgical robots and ablation surgical robots in China. Its core products hold the leading market share nationally, with 36.4% by shipment volume, and have been deployed in nearly 100 medical institutions with over 7,200 completed procedures.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)